Back

The association between the response of lipid-lowering agents and monogenic variants of familiar hypercholesteremia in Taiwan

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Drug therapy (1) Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Ping-Yen Liu

National Cheng Kung University Hospital, Tainan (Taiwan)

7 More presentations in this session

Presentation thumbnail
Prospective validation of a self-report-based model for coronary artery calcium screening and assessment of treatment gaps in lipid-lowering therapy.
Doctor E. Hagberg (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
BW-00112 targeting ANGPTL3 results in prolonged reductions in plasma triglycerides, LDL-C, and remnant-C in Chinese healthy subjects
Ms Y. Li (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM
Professor M. Miller (Philadelphia, US)
Abstract Slides Video
Presentation thumbnail
PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease
Doctor A. Bosch (Erlangen, DE)
Abstract Slides Video
Presentation thumbnail
Effectiveness of statins for primary prevention in the elderly - a propensity score matched cohort study
Doctor D. Leibowitz (Jerusalem, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Cardiovascular risk among individuals with and without genetic mutation for familial hypercholesterolemia: A long-term follow-up study
thumbnail
Congress Presentation
Prevalence, penetrance, and coronary heart disease risk of familial hypercholesterolemia across diverse ancestries
thumbnail
Congress Presentation
Management of children with heterozygous familial hypercholesterolemia worldwide: a meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources